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depending on the type of insulin treatment. They 
used the data from the Department of Obstet-
rics and Women’s Diseases, Gynecologic and Ob-
stetrical University Hospital in Poznań, Poland. 
The department is the biggest perinatal center 
for pregnant women with diabetes in Poland. All 
pregnant women with diabetes from the region 
are immediately referred to the center once the 
pregnancy is confirmed. 
Gutaj et al.5 compared the metabolic charac-
teristics of type 1 diabetes women in the first tri-
mester of pregnancy, who used different types 
of insulin therapy: multiple insulin injections 
(MDIs) or continuous subcutaneous insulin in-
fusion (CSII). This observational study included 
a total of 168 women. The authors aimed to in-
vestigate whether women using CSII before preg-
nancy achieved better metabolic control in early 
pregnancy. The duration of CSII therapy before 
pregnancy was 33 months (range, 6–96 months). 
The authors reported that only 60.6% of women 
on CSII and 45.2% of those on MDI received pre-
conception care. Nonetheless, they demonstrated 
that CSII treatment had beneficial effects not only 
in terms of the reduction in HbA1c levels but also 
in a broader metabolic context in early pregnancy. 
They also highlighted the impact of prepregnan-
cy body mass index on early pregnancy and the 
differences between the two treatment methods.
There is a paucity of data on the risks of fetal 
and infant complications, and the contribution of 
glucose control and other clinical and sociodemo-
graphic factors has been poorly described in Pol-
ish diabetic women. The study by Gutaj et al.5 is 
one of the first studies in Poland involving women 
with type 1 diabetes followed up from early preg-
nancy and receiving comprehensive care. 
There are a number of studies that have de-
scribed the continuous association between 
first-trimester HbA1c levels and the risk of fetal 
The estimated number of diabetes patients 
amounts to more than 21 million worldwide and 
is still growing. Diabetes is the most common 
metabolic disease complicating pregnancy. The 
rate of pregnancies complicated by diabetes is 
rising, reflecting an increase in the prevalence 
of both type 1 and type 2 diabetes as a conse-
quence of the obesity epidemic and increasing 
maternal age. 
The effect of maternal hyperglycemia on fe-
tal development and pregnancy outcome is well 
known. Regardless of the type of diabetes, hyper-
glycemia during pregnancy increases the risk of 
maternal and perinatal adverse outcomes. This 
has considerable implications because preexist-
ing diabetes (both type 1 and type 2) is associat-
ed with a range of pregnancy complications in-
cluding increased risk of macrosomia, congeni-
tal anomaly, delivery by the Caesarean section, 
and  stillbirth. 
It was demonstrated nearly 20 years ago that 
tight control of glycemia and comprehensive care 
from preconception to delivery improves pregnan-
cy outcomes in women with type 1 diabetes.1 The 
comprehensive care of management of hypergly-
cemia in diabetic women before and during preg-
nancy is complex and involves a team of health-
care professionals—doctors, nurses, dietitians, 
and educators. It is crucial to achieve near-nor-
mal glucose levels before and during pregnan-
cy. The treatment goal in pregnancies complicat-
ed by diabetes is to mimic the patterns of glyce-
mia in normal pregnancy. The guidelines for the 
management of diabetes and its complications 
from preconception to postnatal period recom-
mends tight target glucose levels and maintain 
near-normal levels of hemoglobin A1c (HbA1c) be-
low 43 mmol/mol (6.1%).2-4
Gutaj et al.5 investigated metabolic control in 
women with type 1 diabetes in early pregnancy 
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and/or infant death.6-9 Nielsen et al.8 demon-
strated an approximately linear association be-
tween first-trimester HbA1c levels exceeding 
53 mmol/mol (7%) and the risk of an adverse 
outcome.8,9
We need more information about the potential 
effect of treatment methods on the whole preg-
nancy period and infant development. While hy-
perglycemia in pregnancy represents a significant 
impact on health resources, there is still no evi-
dence which tools or technologies are better and 
safer for achieving normoglycemia.
One of the limitations of the study performed 
by Gutaj et al.5 is the small number of studied pa-
tients. Moreover, the study lacks complete data 
on the characteristics of women before a planned 
pregnancy. Effective preconception counseling 
and more aggressive therapeutic targets in diabet-
ic women, especially before conception, are cru-
cial for the prevention of fetal macrosomia and 
poor pregnancy outcomes. The study addresses 
the importance of comprehensive care and ed-
ucational program to achieve glycemic goals in 
type 1 diabetic women and shows useful tools for 
identifying patients who need education. Over 20 
years after the St. Vincent Declaration, women 
with diabetes are still at an increased risk of fetal 
and infant death. Fewer than half of the women 
with preexisting diabetes receive preconception 
care in Poland. To achieve any reduction in poor 
pregnancy outcomes in this patient group, women 
should be educated about the benefits of precon-
ception care. The results reported by Gutaj et al.5 
strongly support the need for achieving good gly-
cemic control before pregnancy.
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